At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 15, 2026 at 08:31 ET
BioMarin discontinued development of VOXZOGO for Noonan syndrome, citing feasibility and the current treatment landscape, with no safety or efficacy concerns. This removes a pipeline asset with uncertain commercial potential, but the decision does not impact approved products like VOXZOGO for achondroplasia or the rest of BioMarin's portfolio. The financial impact is limited to sunk R&D costs, as no material charges or revenue guidance changes were disclosed.
- BioMarin discontinued development of VOXZOGO for children with Noonan syndrome.
- Decision based on study feasibility and current treatment landscape, not safety or efficacy.
- No financial impact or restructuring charges disclosed in the filing.
- VOXZOGO remains approved for achondroplasia; no other pipeline changes announced.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access